Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chugai Of Japan To Make Japan-Specific Version Of Tamiflu

This article was originally published in PharmAsia News

Executive Summary

Japan's Chugai Pharmaceutical plans to produce a version of Roche's Tamiflu (oseltamivir) antiviral modified to deal with the nation's hot and humid weather. Chugai, a subsidiary of Roche, expects to deliver its specially designed version in October in a dry syrup form. The production line to be used is capable of producing enough doses per month to treat 500,000 people. Chugai plans to modify the dry syrup it gets from Switzerland so it can be stored at room temperature instead of needing to be refrigerated. (Click here for more - a subscription may be required

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel